trans-Sialidase de Trypanosoma cruzi (TcTS) pertence à família de glicoproteínas de superfície do parasita e constitui um dos poucos exemplos naturais de glicosiltransferases superficiais encontradas em eucariotes. T. cruzi é incapaz de sintetizar ácido siálico e utiliza esta enzima para retirar este monossacarídeo de glicoconjugados do hospedeiro para sialilar moléculas aceptoras, como mucina-GPI (glicosilfosfatidilinositol), presentes na sua membrana plasmática. Esta enzima é específica em catalisar, preferencialmente, a transferência de ácido siálico para moléculas de mucina, originando ligações -2,3 com moléculas de galactose aceptoras na superfície do parasita. Considerando a heterogeneidade das moléculas de mucina de T. cruzi, é necessário que novas moléculas sejam sintetizadas a fim de que estas atuem como substratos glicopeptídicos, os quais podem levar ao melhor entendimento das interações entre enzima e substratos e permitir o planejamento racional de inibidores seletivos. Por isso, o trabalho foi divido em três rotas sintéticas: (i) preparação do doador de galactose, (ii) preparação dos aceptores-doadores e (iii) acoplamento dos dissacarídeos com aminoácidos aceptores para obtenção dos blocos de construção. Apesar dos objetivos propostos inicialmente não terem sido totalmente alcançados, o trabalho desenvolvido durante esse período permitiu a síntese do doador de galactose (3) em três etapas, aceptor de galactose (6) em cinco etapas, dissacarídeo (11) na glicosilação de 6 com 3, aminoácidos aceptores (13 e 14) e também dos blocos de construção (17 e 18) decorrente do acoplamento de 11 com os aminoácidos aceptores. Não obstante, é importante ressaltar que apesar da extensa rota planejada, porém necessária, a síntese dos blocos de construção é inédita. Portanto, pode-se concluir que o trabalho trouxe relevante contribuição no que diz respeito à química de carboidratos e à disponibilização de dados espectrométricos de compostos orgânicos para a literatura. / Trypanosoma cruzi trans-sialidase (TcTS) belongs to the family of glycoproteins expressed on the surface of the parasite and constitutes one of the few examples of natural surface glycosyltransferases found in eucariotes. T. cruzi can not synthesize sialic acid itself and uses this enzyme to scavenge this monosaccharide from host glycoconjugates to sialylate acceptors molecules, such as GPI (glycosylphosphatidylinositol) mucins, that are present in parasite plasma membrane. This enzyme is specific to catalyze, preferentially, the transference of sialic acid to mucin glycoproteins, generating -2,3-linkages with acceptor galactose molecules in the parasite surface. Considering the heterogeneity of T. cruzi mucin molecules, its necessary to synthesize new compounds that can act as glycopeptide substrates, leading to a better understanding concerning the enzyme and substrates and allow the rational design of some selective inhibitors. Thus, this work was developed in three synthetic routes: (i) the synthesis of galactose donor, (ii) synthesis of donor-acceptors and (iii) coupling between disaccharides and acceptors amino acids in order to obtain building blocks. Despite of some objectives initially proposed had not been accomplished, the developed work during this period allow the synthesis of the galactose donor (3) in three steps, donor-acceptor (6) in five steps, disaccharide (11), acceptors amino acids (13 and 14) and also the building blocks (17 and 18). However, its important highlight that the synthesis of the building blocks by this necessary, but extensive, synthetic route is unpublished. Therefore, it can be concluded that the present work brought rich contribution concerning the carbohydrate chemistry and the availability of spectrometric data of organic compounds to the literature.

La trypanosomiase animale africaine (TAA) est une pathologie qui sévit en Afrique sub-saharienne et qui représente un obstacle majeur à l’élevage du bétail et à la production agricole. Cette pathologie est causée principalement par les parasites T. congolense et T. vivax. Elle affecte le bétail, les animaux domestiques et sauvages, sur un territoire de 10 millions de km2 où ces animaux cohabitent avec l’insecte vecteur, la mouche Tsé-Tsé. L’infection du bétail par ces parasites provoque une anémie sévère pouvant entraîner la mort de l’animal. Dans ce contexte, nous nous sommes intéressés à l’étude des mécanismes impliqués dans le développement de l’anémie lors de l’infection de l’animal par T. vivax. Pour cela, nous avons développé un modèle murin d’infection par T. vivax. Nous avons démontré que l’infection à T. vivax induit d’importantes modifications des acides sialiques présents à la surface des érythrocytes. De plus, nous avons établi un système expérimental « ex-vivo » qui nous a permis de montrer que l’anémie observée au cours de l’infection était dépendante du mécanisme d’érythrophagocytose. Les modifications en acides sialiques des érythrocytes constitueraient un signal de reconnaissance des érythrocytes par les cellules phagocytaires de l’hôte. Par ailleurs, nous avons mis au point des conditions de culture in vitro pour tous les stades parasitaires de T. vivax et T. congolense afin de développer des outils de génomique fonctionnelle. Ces avancées nous ont notamment permis d’identifier des enzymes de type sialidase et trans-sialidase et de détecter les activités enzymatiques correspondantes dans les formes infectieuses de ces parasites. Nous avons exprimé des trans-sialidases recombinantes et démontré qu’elles étaient capables de reproduire in vitro certaines des caractéristiques pathologiques définies in vivo : modifications en acides sialiques des érythrocytes et augmentation de l’érythrophagocytose. Par conséquent, ces travaux ont permis pour la première fois de mettre en évidence un lien entre l’expression des sialidases et trans-sialidases chez le parasite T. vivax et le développement de l’anémie au cours de la TAA. / African animal trypanosomiasis (AAT) is a parasitic disease occurring in sub-Saharan Africa. It impairs livestock development and agricultural production. This disease is mainly caused by T. congolense and T. vivax parasites and is present in livestock, domestic and wild animals, covering an area of over a 10 millions km2, that is known as the Tsé-Tsé fly belt. These infections cause severe anaemia leading to animal death in most cases. In this context, we were interested in unravelling the mechanisms responsible for anaemia caused by T. vivax infection. We developed a murine model for T. vivax infection and our data pointed out important sialic acid modifications of the mouse erythrocyte surface during infection. Additionally, an ex-vivo experimental model was established which proved that anaemia associated with infection depends on erythrophagocytosis. Consequently, we propose that sialic acid modifications associated with infection are involved in the erythrophagocytosis mechanism. Furthermore, in order to develop genetic tools we established in vitro culture conditions for all parasite forms of T. vivax and T. congolense. Parasite cultivation allowed the detection of sialidase and trans-sialidase activity and identifies the presence and function of these proteins in the mammalian form of the parasite. Moreover, trans-sialidase recombinant proteins reproduced some of the T. vivax infection characteristics such as sialic acid modification and increased erythrophagocytosis. Consequently, this work provides the first evidence that links the expression of sialidases and trans-sialidases in T. vivax with the development of anemia during AAT.

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Sialic acids are involved in many biological processes. In glycoproteins and glycolipids they are essential for signalling and mediate molecular interactions as well as being targets for many pathogens such as influenza virus. The synthesis of sialylated glycoconjugates is of great importance. The incorporation of sialic acid through chemical synthesis carries several difficulties, enzymatic strategies using glycosyltransferases are very attractive alternative strategy, and have been used on a broad range of substrates forming glycosidic linkages with regio-and stereo-specificity. The work presented herein shows the study and application of two enzymes, Photobacteriumdamselae alpha2,6-sialyltransferase (Pd2,6ST) and Trypanosoma cruzi trans-sialidase (TcTS) which are used in the synthesis of sialyloligosaccharides. Both enzymes were expressed in E.coli and purified for biotransformations. In the first application new sialylated chromogenic compounds were generated through this enzymatically by using TcTS and a Pd2,6ST. These compounds were used for the detection of neuraminidase activity in a number of biological samples and led to the discovery of neuraminidase activity from Bacillus pumilus and Arthrobacter aurescens, two different bacteria in which the presence of neuraminidases had never been described. Secondly, TcTS was used to study lipid glycosylations. Glycans in biological systems can be associated to complex lipidic microdomains and the presence of these microdomains can affect the activity of some enzymes. In case of Trypanosoma cruzi trans-sialidase, a decreased activity was detected when the acceptor substrate was part of the aggregated lipid rafts compared to activity observed when the reaction was performed using fully dispersed substrate. Thirdly, the sialylation of glycoarrays using Pd2,6ST was studied. For the first time, sialylated glycans with alpha2,6- glycosidic linkages were successfully incorporated into a gold glycoarray platform, which had been previously developed for the label-free detection of carbohydrate-protein interactions. Successful enzymatic incorporation of sialic acids onto the arrays was confirmed with commercial available lectins. Finally, by using the gold glycoarray platform containing both 2,3 and 2,6 linked sialic acids as well as other common glycans, the carbohydrate-binding properties of the surface proteins of the bacterium Lactobacillus reuteri was studied using MALDI-ToF MS techniques. For first time, strong interactions were observed between a mucus binding protein and Neu5Ac alpha2,6-linked glycans, with much weaker binding to 2,3-linked analogues. Such glycan structures have been identified in abundant manner in colon mucins and this study contributes to the understanding of complex interactions between mucins and probiotic organisms as well as pathogenic bacteria. These studies show that glycan arrays can contribute both to the understanding of probiotics as well as to the identification of glycan binding proteins as targets for new drugs.

Cholera is an epidemic infectious diarrhoeal disease that for centuries has proven its frightening ability to cause rapid and widespread loss of human life. All symptoms associated with cholera are a result of rapid dehydration due to infection by pathogenic strains of the bacterium Vibrio cholerae. The damaging effects associated with cholera are mainly attributed to the toxin, which is secreted by the bacterium and infects cells lining the gastrointestinal tract. A sialidase, also secreted by the bacterium, is believed to facilitate toxin uptake by the gastrointestinal epithelium. V. cholerae sialidase is therefore a potential target for therapeutic intervention. A survey of the literature reveals that sialidases from different species share common features with respect to their structure, substrate specificity and catalytic mechanism. The unsaturated sialic acid, Neu5Ac2en, inhibits most exosialidases with a dissociation constant of inhibitor of -10-4 to-10-6 M and has frequently been used as a template in the design of more potent sialidase inhibitors. In the case of V. cholerae sialidase, there have been no inhibitors reported to date that are significantly more potent than Neu5Ac2en itself The present research aimed to develop a range of mimics of Neu5Ac2en, which contain various substituents to replace the C-6 glycerol side chain, as potential inhibitors of V cholerae sialidase. The x-ray crystal structure of V cholerae sialidase was used to explore potential interactions between active site residues and C-6 modified Neu5Ac2en mimetics of known inhibitory potency. Opportunities for interactions within the glycerol side chain pocket in the active site of V cholerae sialidase are discussed. A novel synthetic strategy was developed for the synthesis of a series of glucuronidebased Neu5Ac2en mimetics starting from readily available GIcNAc. This approach was employed for the preparation of Neu5Ac2en mimetics that contained an ether or thioether substituent as replacement of the glycerol side chain of Neu5Ac2en. Progress was also made towards the synthesis of a series of C-6 acylamino Neu5Ac2en mimetics. Analysis by 1H NMR spectroscopy showed that the acylamino derivatives adopted a half-chair conformation that was similar to the conformation of Neu5Ac2en but different to the conformation adopted by the ether and thioether derivatives prepared. The inhibitory activity of the C-6 ether and thioether Neu5Ac2en mimetics prepared was evaluated in vitro using an enzyme assay. It was found that most of the derivatives inhibited V. cholerae sialidase with a K1 of approximately 1O-4 M. The derivatives containing a hydrophobic side chain were found to be slightly more potent compared to derivatives with more hydrophilic side chains. A more detailed study of binding interactions between the C-6 thioether Neu5Ac2en mimetics and V cholerae sialdiase was carried out using STD 1H NMR spectroscopy and computational molecular modelling.

Rational drug design is a powerful method in which new and innovative therapeutics can be designed based on knowledge of the biological target aiming to provide more efficacious and responsible therapeutics. Understanding aspects of the targeted biological agent is important to optimize drug design and preemptively design to slow or avoid drug resistance. Chagas disease, an endemic disease for South and Central America and Mexico is caused by Trypanosoma cruzi, a protozoan parasite known to consist of six separate genetic clusters or DTUs (discrete typing units). Chagas disease therapeutics are problematic and a call for new therapeutics is widespread. Many researchers are working to use rational drug design for developing Chagas drugs and one potential target that receives a lot of attention is the T. cruzi trans-sialidase protein. Trans-sialidase is a nuclear gene that has been shown to be associated with virulence. In T. cruzi, trans-sialidase (TcTS) codes for a protein that catalyzes the transfer of sialic acid from a mammalian host coating the parasitic surface membrane to avoid immuno-detection. Variance in disease pathology depends somewhat on T. cruzi DTU, as well, there is considerable genetic variation within DTUs. However, the role of TcTS in pathology variance among and within DTU’s is not well understood despite numerous studies of TcTS. These previous studies include determining the crystalline structure of TcTS as well as the TS protein structure in other trypanosomes where the enzyme is often inactive. However, no study has examined the role of natural selection in genetic variation in TcTS. In order to understand the role of natural selection in TcTS DNA sequence and protein variation, we sequenced 540 bp of the TcTS gene from 48 insect vectors. Because all 48 sequences had multiple polymorphic bases, we examined cloned sequences from two of the insect vectors. The data are analyzed to understand the role of natural selection in shaping genetic variation in TcTS and interpreted in light of the possible role of TcTS as a drug target.

<p>Atherosclerosis is a complex multi-factorial disease that involves the interaction of many cell types and a plethora of molecular events. Initiation of the disease occurs when circulating LDL gets trapped in the sub-endothelial space of arteries, where LDL is oxidized causing inflammatory responses by endothelial cells. This results in recruitment and differentiation of monocytes into macrophages; macrophages in turn continue to take up cholesterol and propagate inflammation. Such a gloomy milieu of immune cells, lipids, and smooth muscle cells can give rise to atherosclerotic plaques, which then cause stenosis, vascular stiffening and eventually thrombosis. Common risk factors such as cholesterol levels, lifestyle and genetic predisposition can accelerate this potentially life threatening series of events. The downstream long-term effects of atherosclerosis, including heart disease and strokes, are now the number one cause of death in the world. While a large amount of knowledge and evidence is available in understanding this disease, prevention and treatment strategies remain somewhat ineffective. Sialylation of immune cells, lipoproteins and cellular receptors has been previously implicated in metabolic and molecular pathways relevant to atherosclerosis; however, little is known about the functional role of sialidase in these processes. Sialidase cleaves sialic acid, and is a ubiquitously expressed and evolutionarily conserved protein with essential functions in many life forms. In this study, we sought to investigate the impact of sialidase activity on atherosclerosis, emphasizing the interaction of lipid metabolism and inflammation. We have demonstrated a significant role for sialidase in cholesterol iv and lipoprotein metabolism in vivo. Specifically, hypomorphic sialidase mice have increased hepatic storage of lipids and triglycerides, decreased VLDL production, lower circulating LDL levels and alterations in regulation of LDLR. Mice over-expressing hepatic human sialidase have increased atherosclerotic lesion formation, higher serum cholesterol esters and lower levels of hepatic LDLR and SRB-1 protein. In vitro, we have shown that VLDL can induce differentiation and cytokine production in monocytes coupled with an up-regulation of Neu1. Inhibition of sialidase using DANA attenuated VLDL-induced monocyte differentiation and lipid uptake, as well as activation of macrophages, implicating Neu1 in inflammatory processes associated with initiation of atherosclerosis. Furthermore, we have shown that hypomorphic sialidase activity increases LDLR-dependent LDL uptake and cholesterol efflux to HDL in macrophages. We conclude that reduction of sialidase activity can lead to an atheroprotective phenotype with multiple effects on mechanisms involved in disease progression. This work represents novel contributions into delineating both metabolic and inflammatory processes of atherosclerosis and enables the advancement of future treatment strategies.</p> / Doctor of Philosophy (PhD)

<p> Mammalian sialidases are hydrolytic enzymes that initiate the removal of terminal a2-3, a2-6 and a2-8 sialic acid residues from various sialylated glycoconjugates. Sialidases are reportedly involved in numerous cellular functions involving proliferation, differentiation, antigenic expression, inflammation and the tumorigenicity of malignant cells. Recently, sialidase has been implicated in various immune signaling pathways, involving immune effector cells, such as activated lymphocytes and macrophages. The human lysosomal sialidase gene encodes a 46 kD glycoprotein which exists in a multienzyme complex with β-galactosidase and PPCA. Neurodegenerative diseases such as Tay-Sachs and Sandhoff are characterized by the progressive storage of glycoproteins and sialylated oligosaccharides in the nervous system. The induction of inflammatory mediators is a critical step in the pathogenesis of neurodegeneration that remains largely undefined. As such, an in vitro model of Tay-Sachs disease was used to identify potential mediators involved in disease progression. In addition, we have used the THP-1 monocytic cell line as a model of human macrophages which play a key role in potentiating a variety of immune responses. </p> <p> Translocation of neul from lysosomes to the cell surface and the resulting interaction with signaling molecules suggests neul is involved in the regulation of immune activities. We have investigated the role of sialidase on CD44 expression, an inflammation-associated glycoprotein found on the cell surface. Our data indicate that sialidase interacts with CD44 on the cell surface which may contribute to disease progression in Tay-Sachs disease. We illustrate that overexpression of sialidase stimulates interleukin-6 (IL-6) secretion in both human Tay-Sachs neuroglia and THP-1 derived macrophages. Moreover, the sialidase inhibitor 2-deoxy-2, 3-dehydro-N-acetylneuraminic acid (DANA) was found to attenuate IL-6 secretion and sialidase expression in THP-1 derived macrophages. </p> / Thesis / Master of Science (MSc)

Development of atherosclerosis, the hardening of the arteries, is dependent on levels of serum cholesterol, which is regulated by the liver via LDL receptors (LDLR). The expression and internalization of LDL receptors depend on several proteins including PCSK9. In fact, previous studies in our laboratory have shown that NEU1 down regulation leads to LDLR hypersialylation which results in its stabilization via reduced interactions with PCSK9. New evidence suggests that NEU1 which de-sialylates LDLR, may affect the ability of another hepatic receptor, the asialoglycoprotein receptor (ASGR), which is comprised of ASGR1 and ASGR2, to interact with LDLR potentially causing its internalization and therefore reduced ability to take up LDL. We investigated how sialidase plays a role in the interaction of ASGR with LDLR. Knockdown and overexpression experiments suggest that NEU1 allows stabilization of LDLR at the cell membrane via ASGR interactions. Treatment of HepG2 cells with monensin which inhibits recycling from the early endosome, unveiled a new truncated ASGR1 isoform potentially lacking its lectin motif. This may be a novel regulatory step in ASGR biosynthesis that warrants further studies. Lysosomal inhibition with chloroquine resulted in concurrent accumulations of NEU1, LDLR and ASGR1, further suggesting these proteins are biosynthetically connected. Our studies revealed a novel isoform of ASGR1 in membrane fractions of HepG2 cell lysates that can associate with NEU1 and LDLR. The impact of NEU1 and ASGR1 on the function and stability of LDLR might lead to new clues for lowering serum cholesterol and reducing atherosclerosis. / Thesis / Master of Science (MSc)

A doença de Chagas, também conhecida como tripanossomíase americana, é uma das doenças tropicais mais devastadoras e é causada pelo protozoário Trypanosoma cruzi. O parasita expressa uma enzima de superfície, Trypanosoma cruzi trans-sialidase (TcTS), responsável pela transferência de ácidos siálicos de células do hospedeiro para moléculas de -galactose terminais presentes em glicoproteínas de sua superfície. As moléculas de glicoproteína sialiladas estão envolvidas na adesão e subsequente penetração do parasita em células hospedeiras. Logo, TcTS desempenha papel fundamental no reconhecimento e na invasão de células do hospedeiro. Além disso, a ausência de trans-sialidase em seres humanos faz de TcTS um alvo potencial a ser explorado, no entanto nenhum inibidor desta enzima (em concentração nanomolar) é conhecido até o momento. Considerando a importância da unidade de galactose e da função carboxila do ácido siálico para interações no sítio activo de TcTS, focamos na síntese de derivados de galactose com ácido succínico em diferentes posições do anel de açúcar e sua avaliação biológica em TcTS. Além disso, foi proposta uma busca por novos inibidores de TcTS através de técnicas de modelagem molecular, como triagem virtual baseada no sítio ativo da enzima. -D-galactose e -Dgalactopiranosídeo de metila, disponíveis comercialmente, foram tratados com reagentes adequados para fornecer alguns intermediários com apenas uma hidroxila livre em poucas etapas. O tratamento destes compostos com anidrido succínico em piridina levou à formação dos respectivos derivados com ácido succínico em todas as posições do anel galactosídico. Após etapa de desproteção foi obtido apenas o derivado com ácido succínico na posição 4 (85), que foi testado em TcTS por ensaio fluorimétrico in vitro para avaliação de sua atividade inibitória. Adicionalmente, 85 foi testado em ensaios in vitro para avaliação de sua atividade tripanocida e citotóxica. De acordo com os ensaios biológicos, o composto 85 apresentou atividade inibitória promissora (56%) na concentração de 1,0 mM. Esse resultado preliminar foi importante para mostrar que esse tipo de derivado pode atuar como inibidor de TcTS e para orientar a síntese de novos derivados de galactose. O valor da atividade tripanocida foi inferior a 40% (0,5 mM) e não foi observada citotoxicidade na concentração de 0,5 mM. Os estudos de triagem virtual realizados neste trabalho através de simulações de \"docking\" resultaram na seleção das 50 melhores moléculas, baseada na orientação de maior pontuação, dentre 50.000 encontradas na base de dados diverset. O próximo passo envolve novos estudos para filtrar as moléculas mais promissoras para serem testadas em TcTS. / Chagas\' disease, also known as American trypanosomiasis, is one of the most devastating tropical diseases and it is caused by the protozoan Trypanosoma cruzi. The parasite expresses a cell surface enzyme, Trypanosoma cruzi trans-sialidase (TcTS), responsible for the transference of sialic acids from host cells to terminal -galactose molecules present on its glycoprotein surface. The sialylated glycoprotein molecules are involved in the attachment and subsequent penetration of the parasite into host cells. As a result, TcTS plays a key role in the recognition and invasion of host cells. Moreover, the lack of trans-sialidase in humans makes TcTS a potential drug target to be explored, however no strong inhibitors (at nanomolar range) of this enzyme are known to date. Considering the importance of galactose unit and the carboxyl function in sialic acid for interactions in the active site of TcTS, we have focused on the synthesis of galactose derivatives containing succinic acid in different positions of the sugar ring and on their biological evaluation against TcTS. In addition, we have proposed the search for new TcTS inhibitors applying molecular modeling techniques, like virtual screening based on the enzyme´s active site. Commercially available ,-D-galactose and methyl--D-galactopyranoside were treated with suitable reagents to afford some intermediates with just one free hydroxyl group in few steps. Treatment of these compounds with succinic anhydride in pyridine afforded derivatives thereof with succinic acid in all galactosidic ring positions. After deprotection step it was only obtained the derivative containing succinic acid at position 4 (85), which was tested in in vitro TcTS fluorimetric assay for evaluation of its inhibitory activity. In Addition, 85 was tested in in vitro assays for assessment of their trypanocidal activity and cytotoxic. According to the biological assays, compound 85 showed promising inhibitory activity (56%) at 1.0 mM concentration. This preliminary result was important both to show that this type of derivative can act as an inhibitor of TcTS and to guide the synthesis of new derivatives of galactose. The trypanocidal activity value was lower than 40% (0.5 mM) and there was no cytotoxicity at 0.5 mM concentration. The virtual screening studies performed in this work through docking simulations resulted in the selection of the 50 top-ranked molecules, based in the highest score orientation, among 50.000 found at diverset data base. The next step involves new studies to filter the most promising molecules to be tested against TcTS.